Target Now Complete

Every patient is unique, and so is their cancer. Cancer tumors contain biomarkers that are clues to how the tumors will behave when exposed to certain therapies. Knowing these biomarkers can help patients and physicians decide which treatments to consider and even, which treatments to avoid.

Target Now Complete℠ is a molecular profiling and clinical evidence system. The physicians and scientists at Caris Life Sciences™  gather detailed information about each tumor. Then, using advanced data analysis, they identify potential therapies. The methods are based on the latest published clinical findings of thousands of the world's leading cancer researchers.

For example, research shows that breast cancer patients who test positive for HER2 are likely to have a type of breast cancer that is less likely to respond to standard therapy. However, HER2 positive breast cancer may respond to therapies that target HER2 (known as anti-HER2 medications). By identifying the presence of HER2, standard therapies are avoided and patients receive anti-HER2 medications increasing the odds of success.

Based on the molecular profiles of patient tumors, Target Now Complete provides patients and their treating physicians with a list of promising therapies. Together, patients and physicians decide which treatment is right.

To order Target Now Complete testing call 1.800.901.5177 or click here.